Secondary Progressive Multiple Sclerosis (SPMS) - Market Insights, Epidemiology and Market Forecast - 2025

Publisher Name :
Date: 28-Jul-2017
No. of pages: 70
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Secondary Progressive Multiple Sclerosis (SPMS) - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Secondary Progressive Multiple Sclerosis (SPMS) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Secondary Progressive Multiple Sclerosis (SPMS) . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Secondary Progressive Multiple Sclerosis (SPMS) for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Secondary Progressive Multiple Sclerosis (SPMS) market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Secondary Progressive Multiple Sclerosis (SPMS) , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Secondary Progressive Multiple Sclerosis (SPMS) for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Secondary Progressive Multiple Sclerosis (SPMS) 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Secondary Progressive Multiple Sclerosis (SPMS) market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

  • Understanding historical and forecasted epidemiological data for Secondary Progressive Multiple Sclerosis (SPMS) covering 7MM from 2015-2025.

  • Segment level epidemiology and market split for Secondary Progressive Multiple Sclerosis (SPMS) .

  • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Secondary Progressive Multiple Sclerosis (SPMS) .

  • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Secondary Progressive Multiple Sclerosis (SPMS) market trends.

  • Thorough market distribution based on market share for Secondary Progressive Multiple Sclerosis (SPMS) .

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Secondary Progressive Multiple Sclerosis (SPMS) market.

  • To understand the future market competition in the Secondary Progressive Multiple Sclerosis (SPMS) market and Insightful review of the key market drivers and barriers.

  • Organize sales and marketing efforts by identifying the best opportunities for Secondary Progressive Multiple Sclerosis (SPMS) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

Secondary Progressive Multiple Sclerosis (SPMS) - Market Insights, Epidemiology and Market Forecast - 2025

Table of Contents

1. Report Introduction

2. Secondary Progressive Multiple Sclerosis (SPMS) Market Overview at a Glance
2.1. Total Market Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) for 7 MM in 2016
2.2. Total Market Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) for 7 MM in 2025

3. Secondary Progressive Multiple Sclerosis (SPMS)
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment

4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Secondary Progressive Multiple Sclerosis (SPMS) in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Secondary Progressive Multiple Sclerosis (SPMS) in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Secondary Progressive Multiple Sclerosis (SPMS) in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Secondary Progressive Multiple Sclerosis (SPMS) in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Secondary Progressive Multiple Sclerosis (SPMS) in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Secondary Progressive Multiple Sclerosis (SPMS) in United Kingdom

5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices

6. Marketed Drugs for Secondary Progressive Multiple Sclerosis (SPMS)
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status

7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase

8. Overview of Total Secondary Progressive Multiple Sclerosis (SPMS) Market (2016 & 2025)

9. Secondary Progressive Multiple Sclerosis (SPMS) : Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)

10. Market Drivers

11. Market Restraints

12. Appendix

13. Report Methodology

14. Consulting Services

15. Disclaimer

16. About DelveInsight

List of Tables

Table 1: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in United States (2015-2025)
Table 2: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2015-2025)
Table 3: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in France (2015-2025)
Table 4: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2015-2025)
Table 6: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2015-2025)
Table 7: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2015-2025)
Table 8: List of Marketed Drugs for Secondary Progressive Multiple Sclerosis (SPMS)
Table 9: List of Pipeline Phase III Drugs for Secondary Progressive Multiple Sclerosis (SPMS)
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Table 17: Germany Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Table 18: France Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Table 20: Spain Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Table 21: Italy Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Table 22: Japan Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)

List of Figures

Figure 1: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in United States (2015-2025)
Figure 2: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2015-2025)
Figure 3: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in France (2015-2025)
Figure 4: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2015-2025)
Figure 6: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2015-2025)
Figure 7: Diagnosed Cases Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Secondary Progressive Multiple Sclerosis (SPMS)
Figure 9: List of Pipeline Phase III Drugs for Secondary Progressive Multiple Sclerosis (SPMS)
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Figure 17: Germany Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Figure 18: France Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Figure 20: Spain Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Figure 21: Italy Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
Figure 22: Japan Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD, Million (2015-2025)
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Primary Progressive Multiple Sclerosis (PPMS). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Primary Progressive Multiple Sclerosis (PPMS) by development stage, therapy ty......
  • Relapsing Multiple Sclerosis (RMS) - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Relapsing Multiple Sclerosis (RMS)-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Relapsing Multiple Sclerosis (RMS). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Relapsing Multiple Sclerosis (RMS) by development stage, therapy type, route of administration and m......
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Secondary Progressive Multiple Sclerosis (SPMS). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Secondary Progressive Multiple Sclerosis (SPMS) by development stage, ther......
  • Primary Progressive Multiple Sclerosis (PPMS) - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Primary Progressive Multiple Sclerosis (PPMS) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Primary Progressive Multiple Sclerosis (PPMS). The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs ass......
  • Primary Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 28-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Primary Progressive Multiple Sclerosis (PPMS) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current development......
  • Relapsing Multiple Sclerosis (RMS) - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Relapsing Multiple Sclerosis (RMS) -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Relapsing Multiple Sclerosis (RMS) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Relapsing Multiple Sclerosis (RMS). The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Relapsing Multip......
  • Relapsing Multiple Sclerosis (RMS) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 28-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Relapsing Multiple Sclerosis (RMS) - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Relapsing Multiple Sclerosis (RMS) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Relapsing Multip......
  • Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Secondary Progressive Multiple Sclerosis (SPMS) -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Secondary Progressive Multiple Sclerosis (SPMS) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Secondary Progressive Multiple Sclerosis (SPMS). The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical nee......
  • Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jul-2017        Price: US 1500 Onwards        Pages: 40
    DelveInsight's, Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Relapsing Multiple Sclerosis (RMS). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs